As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Pelthos Therapeutics Inc. The largest reported stake is Ligand Pharmaceuticals Incorporated's, at 49.9%. 12 filings are on record since July 3, 2025 (Schedule 13D/A, November 3, 2026).
Sell to companies like Pelthos Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Ligand Pharmaceuticals Incorporated · Sole voting: 5,189,177 · Shared voting: 0 · Sole dispositive: 5,189,177 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-11-03
- · Holder: Ikarian Capital, LLC · Percent: 7.7% · SCHEDULE 13G/A
- · Holder: 3i, LP · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Ikarian Capital, LLC · Percent: 8.4% · SCHEDULE 13G/A
- · Holder: 3i, LP · Percent: 9.9% · SCHEDULE 13G/A
Pelthos Therapeutics Inc. has 12 Schedule 13D or 13G filings on record since 2025-07-03. 5 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 49.9% | 5,189,177 | SCHEDULE 13D/A, 2026-11-03 | 2026-10-30 | |
| 3i, LP | 9.9% | 337,026 | SCHEDULE 13G/A, 2026-05-07 | 2026-03-31 |
| Murchinson Ltd. | 9.1% | 280,000 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
| 8.3% | 250,121 | SCHEDULE 13D/A, 2025-07-03 | 2025-07-01 | |
| Ikarian Capital, LLC | 7.7% | 256,598 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| AME Equities LLC | 0% | 0 | SCHEDULE 13G/A, 2025-08-13 | 2025-06-30 |
Holding shares or following this stake? See who's behind Pelthos Therapeutics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Pelthos Therapeutics Inc. and the records around it.
Pelthos Therapeutics Inc. elsewhere on the record
- Leadership changes May 2026
- Form D filing Nov 2025
- Form D filing Jul 2025
- Who owns it
Companies that share a holder
- Ligand Pharmaceuticals Incorporated also filed stake reports on 1 other company: XOMA ROYALTY CORPORATION (May 2026)
- Murchinson Ltd. also filed stake reports on 2 other companies: Nano Dimension Ltd. (Oct 2026), Valion Bio, Inc. (Jul 2026)
- 3i, LP also filed stake reports on 11 other companies: Tivic Health Systems, Inc. (Sep 2026), Netcapital Inc. (May 2026), zSpace, Inc. (Apr 2026)
Watch Pelthos Therapeutics Inc.
Get an email when Pelthos Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pelthos Therapeutics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Pelthos Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pelthos Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated | 5,189,177 | 0 | 5,189,177 | 0 | SCHEDULE 13D/A, 2026-11-03 |
The latest filing identifies Pelthos Therapeutics Inc. by CUSIP 171126204 and gives its principal executive office as 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM, NC 27703 (SCHEDULE 13D/A, 2026-11-03).
Purpose of Transaction (Item 4)
Ligand Pharmaceuticals Incorporated
Item 4 of the Schedule 13D is hereby supplemented as follows: The Merger Agreement. On October 30, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Credit Card Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), Credit Card Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Issuer ("Merger Sub II"), Merger Partner, and Paragon Biosciences, LLC, as the securityholder representative (the "Securityholder Representative"). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions set forth therein, (i) Merger Sub will merge with and into Merger Partner, with Merger Partner continuing as the surviving corporation and a wholly owned subsidiary of the Issuer (the "First Merger"), and (ii) immediately thereafter, the surviving corporation will merge with and into Merger Sub II, with Merger Sub II continuing as the surviving company and a wholly owned subsidiary of the Issuer (the "Second Merger" and, together with the First Merger, the "Mergers"). The Mergers, taken together, are intended to qualify as a "reorganization" within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended. Merger Consideration. Under the Merger Agreement, the securityholders of Merger Partner will receive, in the aggregate, their allocable share of 5,200,000 shares of Common Stock (the "Castle …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-11-03; the filing has the rest
Ezra Friedberg
"Item 4: Purpose of Transaction" is not being amended by this Amendment No. 1.Item 4 of the SCHEDULE 13D/A filed 2025-07-03
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-03 | Ligand Pharmaceuticals Incorporated | 49.9% | SCHEDULE 13D |
| 2025-07-03 | Ezra Friedberg | 8.3% | SCHEDULE 13D/A |
| 2025-07-08 | 3i, LP | 9.9% | SCHEDULE 13G |
| 2025-08-13 | AME Equities LLC | 0% | SCHEDULE 13G/A |
| 2025-11-10 | Ligand Pharmaceuticals Incorporated | 49.9% | SCHEDULE 13D/A |
| 2025-11-14 | Ikarian Capital, LLC | 6.1% | SCHEDULE 13G/A |
| 2025-11-14 | Murchinson Ltd. | 9.1% | SCHEDULE 13G |
| 2026-02-05 | 3i, LP | 9.9% | SCHEDULE 13G/A |
| 2026-02-17 | Ikarian Capital, LLC | 8.4% | SCHEDULE 13G/A |
| 2026-05-07 | 3i, LP | 9.9% | SCHEDULE 13G/A |
| 2026-05-15 | Ikarian Capital, LLC | 7.7% | SCHEDULE 13G/A |
| 2026-11-03 | Ligand Pharmaceuticals Incorporated | 49.9% | SCHEDULE 13D/A |
Questions about who owns Pelthos Therapeutics Inc.
Who owns Pelthos Therapeutics Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Pelthos Therapeutics Inc.: Ligand Pharmaceuticals Incorporated (49.9%, Schedule 13D/A, filed 2026-11-03), 3i, LP (9.9%, Schedule 13G/A, filed 2026-05-07), Murchinson Ltd. (9.1%, Schedule 13G, filed 2025-11-14), Ezra Friedberg (8.3%, Schedule 13D/A, filed 2025-07-03) and Ikarian Capital, LLC (7.7%, Schedule 13G/A, filed 2026-05-15).
Who are the largest shareholders of Pelthos Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Pelthos Therapeutics Inc. on this page are Ligand Pharmaceuticals Incorporated (49.9%), 3i, LP (9.9%) and Murchinson Ltd. (9.1%).
When did Ligand Pharmaceuticals Incorporated buy into Pelthos Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ligand Pharmaceuticals Incorporated on this page is the Schedule 13D, filed 2025-07-03, reporting 49.9%; its latest, Schedule 13D/A filed 2026-11-03, reports 49.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Pelthos Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 10, 2026 | Leadership change: John M. Gay appointed, Chief Financial Officer, and 1 more | — | Leadership changes | Source |
| November 19, 2025 | Form D, private offering | $18M sold | Form D page | Source |
| July 10, 2025 | Form D, private offering | $50.10M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Pelthos Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.